Skip to main content
SpringerLink
Log in

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors

  • Brief Report
  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity. The median nadir leukocyte count was 1.75 cells/mm3, neutrophil count was 1.55 cells/mm3, hemoglobin was 8.75 gm/dl, and platelet count was 20,500 cells/mm3. Topotecan is not efficacious in the treatment of cisplatin-refractory GCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation of antitumor activity. Cancer Res 49:1465–1469, 1989

    Google Scholar 

  2. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271–291, 1993

    Google Scholar 

  3. Chou T-C, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Nat Cancer Inst 86:1517–1524

  4. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelson D: Phase I clinical and pharmacology study of topotecan given daily for five consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85:1499–1507, 1993

    Google Scholar 

  5. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, New York, NY

    Heidi Sonya Puc, Dean F. Bajorin, George J. Bosl, Alison Amsterdam & Robert J. Motzer

  2. Department of Medicine, Cornell University Medical College, New York, NY, USA

    Heidi Sonya Puc, Dean F. Bajorin, George J. Bosl, Alison Amsterdam & Robert J. Motzer

Authors
  1. Heidi Sonya Puc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean F. Bajorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George J. Bosl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alison Amsterdam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Puc, H.S., Bajorin, D.F., Bosl, G.J. et al. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest New Drugs 13, 163–165 (1995). https://doi.org/10.1007/BF00872866

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00872866

Key words

Search

Navigation